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Patients treated in Peru for multidrug-resistant tuber-
culosis (MDR-TB) were followed-up for a median of 67
months. Among 86 patients considered cured after comple-
tion of treatment, 97% remain healthy; 1 patient relapsed.
Employment increased from 34% before treatment to 71%.
We observed favorable long-term outcomes among MDR-
TB patients.
I
ncreasing awareness of the rising global rates of mul-
tidrug-resistant tuberculosis (MDR-TB) has led to a con-
certed international effort to confront this disease,
particularly in countries with a high incidence of TB (1–3).
Nonetheless, despite cure rates >80% in some programs,
MDR-TB patients tend to have chronic disease and require
prolonged therapy. 
Little is known about the long-term follow-up of
patients treated for MDR-TB, including rates of relapse and
chronic disability among cured persons. Among patients
treated for pansusceptible TB, chronic disability caused by
pulmonary sequelae and malnutrition can be substantial (4).
Given the prolonged nature of MDR-TB, one might expect
higher rates of chronic disability among patients with drug-
resistant TB compared with those with pansusceptible TB.
To explore these questions, we conducted long-term fol-
low-up, defined as follow-up for a minimum of 4 years
after treatment was initiated, of MDR-TB patients who
received individualized therapy in Lima, Peru (1).
The Study
We performed a retrospective study among all patients
who initiated individualized, community-based MDR-TB
therapy from August 1, 1996, to March 1, 2000. The
details of patient identification, enrollment, and treatment
are described elsewhere (5). Patients were resistant to a
median of 5 drugs (range 2–9). Regimens generally includ-
ed at least 5 drugs to which the infecting isolate was sus-
ceptible, and treatment duration was 18–24 months.
Routine follow-up after completion of MDR-TB therapy
included 1) routine smear microscopy and culture on spu-
tum samples 1 month after completion of treatment and
then every 6 months for 1 year; 2) subsequent smear
microscopy, culture, and clinical evaluation by a TB physi-
cian for any episode of potential TB symptoms, e.g., a res-
piratory illness lasting >14 days, hemoptysis, or weight
loss of unclear cause; and 3) continued contact with Socios
en Salud (the community-based organization working with
the Ministry of Health on this MDR-TB treatment project)
through the network of health promoters, patient group
therapy sessions, and a social assistance program. Thus,
loss to follow-up or undocumented medical attention for
respiratory illness is rare.
When reporting cohort outcomes, the MDR-TB work-
ing group recommends follow-up for 2 years from the time
of treatment initiation when reporting cohort outcomes (6);
however no international definition of long-term follow-up
for MDR-TB cohorts exists. Therefore, we defined long-
term follow-up as twice the duration set forth by the MDR-
TB working group. 
We conducted a chart review to determine TB-related
symptoms and employment status of persons recorded at
baseline by the intake physician before they received
MDR-TB therapy. In addition to data obtained through
routine patient follow-up as per program norms described
above, Socios en Salud staff involved in the social assis-
tance program, members of group therapy sessions, and
health promoters were interviewed to obtain additional fol-
low-up information about the patients, including income,
employment status, and household information. Acommu-
nity health worker conducted home visits to interview all
patients; patients were questioned about current symptoms
as well as their socioeconomic status. The study was
reviewed and approved by the institutional review board at
Harvard Medical School; local institutional review was not
required.
Among 120 persons enrolled in this study, 23 patients
died during treatment, and 1 person remained in culture-
negative treatment at the time of analysis. Two patients
(both of whom had defaulted from treatment) were lost to
follow-up. 
Data are reported on the remaining 96 (80%) patients
who were alive at the time of stopping MDR-TB therapy.
Patients were followed for a median (95% confidence
interval) of 67 (47–88) months after initiation of treatment
and a median of 46 (3–84) months after completion of
treatment. As summarized in the Table, 86 (72%) patients
were considered cured, 9 (8%) defaulted from treatment,
and 1 (1%) had failed treatment. 
Among those who were considered cured at the time of
treatment completion, 83 (97%) are currently healthy. One
patient relapsed 1 month after completion of treatment; this
patient refused retreatment and subsequently died of TB.
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Peru; and §Harvard Medical School, Boston, Massachusetts, USATwo other cured (culture-negative) patients later died (1 of a
narcotic overdose and the other of respiratory insufficiency).
Of the 9 patients who defaulted, 3 were culture-positive
at the time they abandoned treatment. Among the 9
defaulters, 5 died (4 from TB and 1 by suspected suicide),
2 are currently culture negative, and 2 were lost to follow-
up since the time of treatment default. One patient was
considered a treatment failure and, despite further retreat-
ment regimens, subsequently died of TB. 
Among 96 patients who were alive at treatment com-
pletion, 85 (89%) currently remain healthy. Thus, among
the entire cohort of 120 patients enrolled during the study
period, favorable long-term outcome was observed among
71%. Four patients experienced long-term sequelae:
hemoptysis caused by aspergilloma necessitating pul-
monary resection (1 patient), bronchiectasis and recurrent
respiratory infections (2 patients), and bronchopleural fis-
tula after pneumonectomy (1 patient). 
In addition to medical care, Socios en Salud provides
social assistance with financial support to resume work
and pursue studies. Of the 96 patients, 21 patients (22%)
received financial aid to pursue work or study, and 13
(14%) have had children since they were cured.
Employment improved from 34% before therapy to 71%
after therapy. None of the persons employed before start-
ing MDR-TB treatment have lost their jobs because of
work disruption caused by their TB therapy.
Conclusions
Although MDR-TB presents a major challenge to TB
control, effective treatment can result in cure. Long-term
follow-up is important for understanding the long-term
efficacy of treatment and the overall impact of this disease
on patients’ physical and socioeconomic well-being. 
This study has several interesting findings. First, unlike
previous reports of high death rates associated with MDR-
TB, most of our patients met the definition of cure upon
completion of treatment. Second, few patients who were
cured at treatment completion had long-term sequelae or
relapse. Third, most patients were able to resume work or
studies and participate in family roles as parents and care-
takers. Finally, the default rate was low (7.5%). 
We recognize the limitations of this study. First, the
cohort was small, and longer follow-up would be useful in
determining if these indicators of physical and social
recovery are sustained. Second, several patients were lost
to follow-up; thus, the outcome of these patients is still not
well characterized. Finally, these results may not be appli-
cable to other situations, where the socioeconomic situa-
tion determines, in large part, the ability of a patient to
resume work and studies. 
With access to laboratory results to guide individualized
therapy for persons with MDR-TB in the context of strong
community-based support, the outcomes observed in Peru
are encouraging. These outcomes favor the implementation
of similar MDR-TB treatment programs globally. 
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